Jaw Pain and Heart Attack: Symptoms, Causes, and Treatment



catheterization procedure :: Article Creator

Scottsdale Hospital Is Arizona's First Non-clinical Site To Perform Heart Surgery With New Medical Tool

PHOENIX — A Scottsdale hospital recently became the first non-clinical trial site in Arizona to use a new medical tool to perform a tricuspid heart valve replacement.

HonorHealth Scottsdale Shea Medical Center doctors used the Edwards EVOQUE system, which the FDA approved in February, for the breakthrough procedure. The new technology's primary purpose is to prevent the backflow of blood in the upper-right chamber of the heart.

HonorHealth interventional cardiologist Haidar Yassin said about 1.6 million United States citizens deal with moderate to severe forms of this blood backflow, otherwise known as tricuspid regurgitation.

"When (tricuspid regurgitation) becomes moderate or severe, it can be life limiting and potentially life threatening," Yassin said in a press release Wednesday. "Through this treatment, we can improve quality of life, relieve symptoms such as tiredness, shortness of breath and fatigue."

Through the use of a catheter, HonorHealth is hoping to make most forms of open-heart surgery obsolete and effectively lead to less pain and faster recovery for all patients.

The milestone procedure was spearheaded by Yassin and HonorHealth network director Robert Riley at the HonorHealth Scottsdale hospital off of the Loop 101 and Shea Boulevard.

"HonorHealth Heart Care is a leader is aortic, mitral and pulmonary valve care, and this is the next logical step to provide complete heart care for our patients," Riana Kielly, HonorHealth hospital administrator, said in the release. "These innovative procedures require collaboration between multiple specialists and teams before, during and after the procedure. At HonorHealth, we already have these teams in place."

The HonorHealth health care network serves more than five million patients in the Phoenix area.

We want to hear from you.

Have a story idea or tip? Pass it along to the KTAR News team here.

Share


Global Catheter-Directed Thrombolysis Market To Reach USD 808 Million By 2033, Driven By Growing Demand For Minimally Invasive ProceduresFMI

Catheter-Directed Thrombolysis MarketCatheter-Directed Thrombolysis Market

The global catheter-directed thrombolysis market is poised for significant growth, with a projected Compound Annual Growth Rate (CAGR) of 5.9%. Valued at USD 454.8 million in 2023, the market is expected to reach an estimated USD 808 million by 2033, according to the latest market analysis.

Catheter-directed thrombolysis, a minimally invasive procedure for treating blood clots, is rapidly gaining traction in the medical field. The technique, which involves the precise delivery of thrombolytic agents directly to the clot site, ensures rapid and effective clot dissolution while minimizing systemic side effects. Its effectiveness, combined with its safety profile, has led to widespread adoption by healthcare providers, presenting a superior alternative to traditional clot treatments.

Gain Access to Market Trends: Request Your Sample Report!

"This procedure's unparalleled efficacy has made it a go-to solution for the treatment of various thrombotic conditions, including deep vein thrombosis (DVT) and pulmonary embolism (PE)," says a Future Market Insights. "With an anticipated CAGR of 5.9%, the catheter-directed thrombolysis market is poised for significant expansion over the next decade."

The growing prevalence of DVT and PE, along with an increasing preference for minimally invasive techniques, is driving the demand for catheter-directed thrombolysis. The procedure not only reduces hospital stays but also accelerates recovery times, making it a preferred choice for both patients and healthcare providers. As such, the market is witnessing a surge in adoption across hospitals and specialty centers worldwide.

The market's impressive growth prospects are underlined by continuous innovation in catheter-based technologies and expanding applications across a range of medical conditions. These factors are expected to open up new avenues for medical device manufacturers, healthcare providers, and investors alike.

As the market continues its upward trajectory, key players in the catheter-directed thrombolysis space are expected to focus on technological advancements, strategic partnerships, and expanding their geographic footprints to capitalize on the expanding opportunities.

Top Highlights from the FMI's Analysis of the Catheter-directed thrombolysis industry:

  • The North American catheter-directed thrombolysis industry is expected to gain 53.4% market share, with the United States enjoying the leading position in the region and globe by attaining 47% in the global market.
  • Although Europe's market share is less than half of North America's, i.E., Europe garnered a 24.1% market share in 2022. The region still holds a prominent position in the market.
  • Germany leads the European market with a market share of 4.7%.
  • Japan has a value share of 3.1%, attracting businesses to delve deep into the market for revenue prospects.
  • Australia's growth rate in the market, as estimated by FMI, is expected to be 5.2% CAGR over the forecast period.
  • China is expected to expand at a robust pace of 7.1% over the forecast period.
  • India, another Asian country, is expected to expand at a CAGR of 5.8% from 2023 to 2033.
  • The United Kingdom is expected to expand at a CAGR of 4.1% over the forecast period.
  • Under the delivery mode category, direct delivery to the blood clot segment is expected to garner a market share of more than 62.8% over the forecast period.
  • Based on end users, the hospital segment is expected to grab a value share of more than 47.8%.

    • Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

    Key Players in the News:

  • In August 2022, Boston Scientific Corporation obtained Obsidio, Inc., which is a privately-owned firm that has created Gel Embolic Material (GEM) technology for the coagulum of blood vessels in the peripheral circulatory system.
  • In July 2020, iVascular S.L.U introduced its sergeant peripheral support catheter for patients suffering from peripheral artery disorder or difficult anatomy during interventional and diagnostic procedures. The device delivers brilliant pushability and torque capacity due to its tapered shaft design.

    • Some of the key participants present in the market include:

  • AngioDynamics Inc.
  • Boston Scientific Corporation
  • iVascular SLU
  • Straub Medical AG

    • Key Segments:

    By Delivery Mode:

  • Direct Delivery to Blood Clot Catheter-directed Thrombolysis
  • Catheter-directed Thrombolysis by Positioning Medical Device at Clot Site

    • By Indication:

  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Strokes
  • Other Indications

    • By End User:

  • Hospitals
  • Surgical Centers
  • Radiology Clinics

    • By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa
  • Europe

    • About Future Market Insights (FMI)

    Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

    Contact Us:        

    Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-347-918-3531For Sales Enquiries: sales@futuremarketinsights.ComWebsite: https://www.Futuremarketinsights.ComLinkedInTwitterBlogsYouTube


    Catheter Ablation Superior To Drugs In Treating Ventricular Tachycardia: New Study Highlights CANet's Role In Research Success

    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.





    -

    Comments

    Post a Comment

    Popular Posts

    Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

    Image
    coronary artery elasticity :: Article Creator Intravascular Imaging Can Improve Outcomes For Complex Stenting Procedures In Patients With High-risk Calcified Coronary Artery Disease Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronary artery disease than conventional angiography, the more commonly used technique. Those are the findings from the largest clinical trial of its kind comparing the two methods during percutaneous coronary intervention (PCI). The "ECLIPSE" trial results were presented on Monday, March 31, in a Late Breaking Clinical Trial Session at the American College of Cardiology Scientific Session (ACC.25) in Chicago. These results could shift treatment options for high-risk patients. "The ECLIPSE trial shows that use of IVI to guide coronary stenting in severely calcified lesions prevents death, stent...
    Read more

    Effects of hot weather, humidity on blood pressure, heart

    Image
    salt for bp patients :: Article Creator The Truth About Salt, Blood Pressure And Your Health For years we've been told to push away the salt shaker. Toss those pretzels. Say goodbye to your beloved pickle spears. But what if everything we thought we knew about salt and blood pressure isn't exactly right? The relationship between that little white crystal and your heart health is way more complicated than most of us realize. Let's face it—salt makes everything taste better. From that morning avocado toast to the caramel you secretly crave, a dash of salt brings food to life. But somewhere along the way, salt got a seriously bad reputation. It became the dietary equivalent of that friend who always causes drama at parties. The sodium saga Remember when your grandma warned you about eating too much salt? She wasn't making it up. Traditional medical wisdom has long connected high sodium intake with increased blood pressure. The th...
    Read more

    Atherosclerosis common in adults without heart disease, symptoms

    Image
    clinical trials day :: Article Creator Everyday Drug Discovery: How Tech Expands The Potential Of Clinical Trials And Recentres Participants Throughout my career in the development and implementation of technological solutions to support clinical research, I've been lucky enough to work closely with a wide range of so-called "stakeholders" in the clinical trial lifecycle, from regulators, drug development research teams, site staff, and patients.  While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients' willingness to sacrifice their time and adapt their care plans to take part in clinical trials, fully understanding they might not directly benefit from the treatment being tested, though so often desperately hoping they do. Patients recognise the importance of clinical research to the long term success in treating diseases of all kinds, and in turn the industry has t...
    Read more